Opdivo’s Japan Patent to Expire in 2031, Ono to Cover LOE with New Launches: Chief

Ono President Gyo Sagara Ono Pharmaceutical's flagship cancer drug Opdivo (nivolumab) will lose its patent protection in Japan in 2031, but the company will work to counter its revenue cliff with the global launches of new products, President Gyo Sagara...read more